相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo
Min H. Kang et al.
BLOOD (2007)
BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts
T. M. Kohl et al.
LEUKEMIA (2007)
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells
M. P. Kline et al.
LEUKEMIA (2007)
A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
A. W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
Ronald Koschny et al.
CLINICAL CANCER RESEARCH (2007)
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan
Suzanne Trudel et al.
CLINICAL CANCER RESEARCH (2007)
Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma
Alexander H. Stegh et al.
GENES & DEVELOPMENT (2007)
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
Victoria Del Gaizo Moore et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao et al.
NATURE (2006)
CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas
Navid Redjal et al.
CLINICAL CANCER RESEARCH (2006)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group
Agop Y. Bedikian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-Deficient and PTEN-intact glioblastoma cells
Maria Y. Wang et al.
CANCER RESEARCH (2006)
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
Patrick Y. Wen et al.
CLINICAL CANCER RESEARCH (2006)
Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas
L. Doherty et al.
NEUROLOGY (2006)
TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme
Jos M. A. Kuijlen et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Recent advances in the treatment of malignant astrocytoma
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death
F Manero et al.
CANCER RESEARCH (2006)
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastorna multiforme
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas
HN Zhen et al.
CANCER (2005)
Sensitization for γ-irradiation-induced apoptosis by second mitochondria-derived activator of caspase.
S Giagkousiklidis et al.
CANCER RESEARCH (2005)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells
RD Rao et al.
NEOPLASIA (2005)
mTOR controls FLIPs translation and TRAIL sensitivity in glioblastoma multiforme cells
A Panner et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Angiogenesis and apoptosis in glioma:: Two arenas for promising new therapies
O Bögler et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs
VJN Bykov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
E Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
SM Chang et al.
INVESTIGATIONAL NEW DRUGS (2005)
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
DA Haas-Kogan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme
H Athanassiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor
M Holdhoff et al.
BLOOD CELLS MOLECULES AND DISEASES (2005)
TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation
VK Puduvalli et al.
APOPTOSIS (2005)
Apoptosis pathways in cancer and cancer therapy
KM Debatin
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Cell death: Critical control points
NN Danial et al.
CELL (2004)
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection
CW Hendrix et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms
A Chakravarti et al.
ONCOGENE (2004)
A small molecule Smac mimic potentiates TRAIL- and TNFα-mediated cell death
L Li et al.
SCIENCE (2004)
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix
LD Walensky et al.
SCIENCE (2004)
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy
JJ Raizer et al.
NEURO-ONCOLOGY (2004)
Identification of human brain tumour initiating cells
SK Singh et al.
NATURE (2004)
Apoptosis in gliomas: molecular mechanisms and therapeutic implications
JP Steinbach et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
Phase II trial of gefitinib in recurrent glioblastoma
JN Rich et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model
R Saito et al.
CANCER RESEARCH (2004)
Supratentorial high-grade astrocytoma and diffuse brainstem glioma: Two challenges for the pediatric oncologist
A Broniscer et al.
ONCOLOGIST (2004)
CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death
J Wischhusen et al.
ONCOGENE (2003)
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors
JB Rubin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Expression of antisense bcl-2 cDNA abolishes tumorigenicity and enhances chemo sensitivity of human malignant glioma cells
CJ Zhu et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2003)
Senescence apoptosis and therapy - cutting the lifelines of cancer
CA Schmitt
NATURE REVIEWS CANCER (2003)
Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death
ZH Jiang et al.
JOURNAL OF NEUROCHEMISTRY (2003)
Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells
P Guensberg et al.
CHEMOTHERAPY (2002)
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo
S Fulda et al.
NATURE MEDICINE (2002)
The prognostic influence of bcl-2 in malignant glioma
FE McDonald et al.
BRITISH JOURNAL OF CANCER (2002)
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
VJN Bykov et al.
NATURE MEDICINE (2002)
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
D Lawrence et al.
NATURE MEDICINE (2001)
Medical progress: Brain tumors
LM DeAngelis
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers
CW Hendrix et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
M Jo et al.
NATURE MEDICINE (2000)
分享论文
